Search results
Results from the WOW.Com Content Network
Cisplatin is administered intravenously as short-term infusion in normal saline for treatment of solid and haematological malignancies. It is used to treat various types of cancers, including sarcomas, some carcinomas (e.g., small cell lung cancer, squamous cell carcinoma of the head and neck and ovarian cancer), lymphomas, bladder cancer, cervical cancer, [9] and germ cell tumors.
1) Platinum-based compounds, namely oxaliplatin, cisplatin, and carboplatin (which is noticeably less neurotoxic than cisplatin), are used to treat several types of solid tumors, such as stomach, liver, lung, ovarian, brain, and uterine cancers. [3] These agents can damage dorsal root ganglia neurons by forming adducts with nuclear and ...
Etoposide, a semi-synthetic derivative of epipodophyllotoxin is commonly used to study this apoptotic mechanism and include: Etoposide; Teniposide; Both etoposide and teniposide are naturally occurring semi-synthetic derivatives of podophyllotoxins and are important anti-cancer drugs that function to inhibit TopII activity. [67]
Etoposide, sold under the brand name Vepesid among others, is a chemotherapy medication used for the treatments of a number of types of cancer including testicular cancer, lung cancer, lymphoma, leukemia, neuroblastoma, and ovarian cancer. [2] It is also used for hemophagocytic lymphohistiocytosis. [3] It is used by mouth or injection into a ...
Macmillan Education was created as an imprint and division of the broader Macmillan publishing business in the UK in the early 1970s. [1] [2] In 1994 it became legally framed within Macmillan Education Ltd, a company in the Macmillan group. [3]
Etoposide, an epipodophyllotoxin. Epipodophyllotoxins are substances naturally occurring in the root of American Mayapple plant (Podophyllum peltatum). Some epipodophyllotoxin derivatives are currently used in the treatment of cancer. These include etoposide and teniposide. They act as anti-cancer drugs by inhibiting topoisomerase II. [1]
Carboplatin, a cisplatin analogue, was developed by Bristol Myers Squibb and the Institute of Cancer Research in order to reduce the toxicity of cisplatin. [6] [22] It gained U.S. Food and Drug Administration (FDA) approval for carboplatin, under the brand name Paraplatin, in March 1989. Starting in October 2004, generic versions of the drug ...
Maurice Slevin is a British medical oncologist specialising in the treatment of breast, ovarian and gastrointestinal cancers. [1] He has made contributions to the field through both his clinical practise and research. [2]